Endo International PLC (NASDAQ:ENDP) (TSE:ENL) dropped 3.4% on Friday . The company traded as low as $5.93 and last traded at $6.31. Approximately 6,401,585 shares traded hands during trading, a decline of 13% from the average daily volume of 7,377,483 shares. The stock had previously closed at $6.53.

Several equities research analysts have recently commented on the company. Zacks Investment Research upgraded Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective for the company in a research note on Wednesday, October 11th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Mizuho restated a “buy” rating and issued a $14.00 price objective (down from $19.00) on shares of Endo International PLC in a research note on Tuesday, September 12th. ValuEngine lowered Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Endo International PLC in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price objective for the company. Four analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have assigned a buy rating to the company’s stock. Endo International PLC currently has a consensus rating of “Hold” and a consensus price target of $12.64.

The firm has a market cap of $1.33 billion, a price-to-earnings ratio of 1.20 and a beta of 0.53. The company has a debt-to-equity ratio of 10.20, a quick ratio of 0.80 and a current ratio of 1.02.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million during the quarter, compared to analysts’ expectations of $832.66 million. During the same quarter in the prior year, the firm posted $0.86 earnings per share. The business’s quarterly revenue was down 4.9% on a year-over-year basis. analysts predict that Endo International PLC will post 3.54 EPS for the current year.

In other Endo International PLC news, COO Terrance J. Coughlin bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the transaction, the chief operating officer now directly owns 181,369 shares in the company, valued at $1,396,541.30. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Blaise Coleman bought 6,500 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were acquired at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the transaction, the chief financial officer now owns 13,729 shares in the company, valued at $108,321.81. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC boosted its position in shares of Endo International PLC by 1.9% during the 2nd quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after purchasing an additional 15,928 shares in the last quarter. Diamond Hill Capital Management Inc. boosted its position in shares of Endo International PLC by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after purchasing an additional 228,426 shares in the last quarter. TIAA CREF Investment Management LLC boosted its position in shares of Endo International PLC by 1.6% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after purchasing an additional 10,387 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Endo International PLC by 4.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 581,552 shares of the company’s stock valued at $6,497,000 after purchasing an additional 27,414 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of Endo International PLC by 93.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock valued at $6,314,000 after purchasing an additional 273,024 shares in the last quarter. Institutional investors own 90.29% of the company’s stock.

WARNING: “Endo International PLC (ENDP) Shares Down 3.4%” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/endo-international-plc-endp-shares-down-3-4/1678429.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.